期刊文献+

血清降钙素原PCT检测在发热待查病因初筛的临床应用 被引量:25

The clinical application of serum procalcitonin in the differntiation of the cause of fever patients
下载PDF
导出
摘要 目的探讨血清降钙素原(PCT)检测在发热待查疾病的鉴别诊断价值。方法对200例因发热收住院患者采用胶体金比色法检测患者血清PCT水平,检测结果 4个等级,正常值<0.5 ng/ml,超过0.5 ng/ml为阳性阈值,>10 ng/ml考虑重度感染。结果在非细菌感染性疾病组中阳性率为10%、其浓度以0.5~2 ng/ml为主;细菌性感染组阳性率为58.6%,以0.5~2、2.0~10.0 ng/ml为主。非细菌感染性疾病组及细菌感染组血清PCT水平差异有统计学意义(P<0.01)。结论非细菌感染性疾病患者血清中PCT水平不升高或轻度升高,而细菌性感染患者及重度感染患者血清中PCT水平则明显升高,尤其以重度感染组患者为甚。 Objective To evaluate the value of serum procalcitonin analysis in the differentiation of the cause of fever patients.Methods 200 cases of hospitalized patients with fever received gold assay for measuring serum PCT levels amd the results were divided into 4 grades.0.5 ng/ml was regarded as the positive threshold value and 10 ng/ml considered severe infection.Results The positive rate of serum procalcitonin in the patients with non-bacterial infection and bacteria infection were 10%,58.6%,respectively.Mainly concentrated in the concentration were 0.5 ng/ml and 0.5~2,2.0~10.0 ng/ml respectively for the two groups of non-bacterial infection and bacteria infection(P0.01).Conclusion Patients with non-bacterial infection have nomal or slightly elevated serum PCT levels,whereas patients with bacteria infection have significantly elevated,particularly in patients with severe infection.
出处 《临床肺科杂志》 2011年第12期1847-1848,共2页 Journal of Clinical Pulmonary Medicine
关键词 降钙素原 感染性疾病 细菌感染 发热 procalcitonin infectious diseases bacterial infections fever
  • 相关文献

参考文献6

二级参考文献24

  • 1常春,姚婉贞,陈亚红,刘振英,张晓伟.慢性阻塞性肺疾病患者急性加重期血清降钙素原水平的变化及临床意义[J].中华结核和呼吸杂志,2006,29(7):444-447. 被引量:93
  • 2郭世春,吴蕊,戴禄寿,刘艳萍,蔡雄,王国俊.呼吸机相关肺炎患者血清前降钙素变化检测的临床意义[J].临床军医杂志,2006,34(6):684-685. 被引量:6
  • 3Delevaux I, Andre M, Colombier M, et al. Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes. Ann Rheum Dis ,2003,62 (4) :337 - 340.
  • 4Jereb M, Kotar T. Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia. Wien Klin Wochenschr,2006,118 (5-6) :170 - 174.
  • 5Hirakata Y, Yanagihara K, Kurihara S, et al. Comparison of usefulness of plasma procaleitonin and C-reactive protein measurements for estiroation of severity in adults with community-acquired pneumonia. Diagn Microbiol Infect Dis, 2008,61 ( 2 ) : 170 - 174.
  • 6Christ-Crain M,Stolz D, Bingisser R,et al. Procalcitonin guidance of antibiotic therapy in Communtity-acquired pneumonia:a tandomized trial. Am J Respir Crit Care Med ,2006,174 (1) :84 -93.
  • 7Menendez R, Cavaleanti M, Reyes S, et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax,2008, 63(5) :447 -452.
  • 8Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD : a randomized , controlled trial comparing procalcitonin-guidance with standard therapy. Chest,2007,131 ( 1 ) : 9-19.
  • 9Boussekey N, Leroy O, Alfandari S, et al. Procalcitonin kinetics in the prognosis of severe community - acquired pneumonia. Intensive Care Med,2006,32(3) :469 -472.
  • 10Oppert M, Reinicke A, Muller C, et al. Elevations in procaleitonin but not C-reactive protein are associated with pneumonia after cardiopulmonary resuscitation. Resuscitation ,2002,53 (2) : 167 - 170.

共引文献83

同被引文献155

引证文献25

二级引证文献180

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部